News
In the News: HIT Consultant Shares Survey Results on Tech Adoption
2023 survey by Advarra highlights increasing tech burdens in clinical research sites since 2018, with calls for industry collaboration.
In the News: Wendy Tate Share Insights about the Study Activation Survey
Wendy Tate shares survey insights on clinical trials tech adoption, eConsent, and new tools.
In the News: Elisa Cascade Explores Advancements in Patient Data Sharing with ACRP
Advarra's patient portal enhances clinical trial transparency by sharing vital data, fostering real-time collaboration among stakeholders.
In the News: Elisa Cascade Interview in The Clinical Trial Vanguard
New Clinical Trial Industry Survey Reveals Increased Burdens on Sites
Explore Advarra's 2023 Survey insights on rising site burdens in clinical research, tech challenges, and the path towards streamlined trials.
Advarra Launches Next-Generation Technology to Align Patients, Sites and Sponsors in Clinical Trials
Developed with industry stakeholders, Longboat v2.2 provides patients with easy access to their study information in one site-focused solution COLUMBIA,...
Advarra Announces Appointment of Elisa Cascade as Chief Product Officer
Leadership appointment demonstrates Advarra’s commitment to supporting the growth of its technology offerings across the clinical research ecosystem (COLUMBIA, MD.)...
Advarra Announces Appointments of Scott Hoffman as Chief Commercial Officer and Scott Uebele as Chief Operating Officer
Key leadership appointments highlight continued commitment to offering connected solutions across the clinical research ecosystem and providing best-in-class operational delivery to customers
SubjectWell Features Advarra Experts James Riddle and Luke Gelinas in White Paper
In a recent article, SubjectWell interviewed Advarra's James Riddle and Luke Gelinas, Compensation norms create inequity in clinical trials".
Updated Advarra Fee Schedules Now Available
TAdvarra’s updated fee schedules for IRB, IBC, DMC, and EAC are now available. The new fee schedules are effective January 1, 2023.
FDA Proposes Revised IRB Regulations, Including Required sIRB for Multisite Trials
The FDA released two proposed rules intended to partially harmonize its current regulations with the Revised Common Rule.
Advarra Achieves 1,000+ Site Milestone for its Gene Therapy Ready Network
Research involving gene therapy-based treatments can start more quickly with Advarra’s growing network of registered research sites.
Subscribe to our monthly email
Receive updates monthly about webinars for CEUs, white papers, podcasts, and more.
Advancing Clinical Research: Safer, Smarter, Faster™
Copyright © 2024 Advarra. All Rights Reserved.